Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
14. April 2023 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. März 2023 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
30. März 2023 16:05 ET
|
Spero Therapeutics, Inc.
Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr...
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
13. März 2023 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
06. März 2023 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28. Februar 2023 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics to Present at Upcoming Investor Conferences
28. Februar 2023 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31. Januar 2023 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22. Dezember 2022 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
22. November 2022 08:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and...